<DOC>
	<DOCNO>NCT01684202</DOCNO>
	<brief_summary>OPC-41061 administered patient volume overload associated cancer , first dose-escalation subsequently 6 consecutive day fix dose urine volume increase investigate efficacy , pharmacokinetics , pharmacodynamic effect , safety determine effective initial maintenance dose OPC-41061 .</brief_summary>
	<brief_title>A Multicenter , Open-label , Dose-finding Trial OPC-41061 Investigate Efficacy , Pharmacokinetics , Pharmacodynamics , Safety Patients With Carcinomatous Edema ( Phase 2 )</brief_title>
	<detailed_description />
	<mesh_term>Edema</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<criteria>Subjects judge cancer biopsy cytology Subjects carcinomatous ascites Male female subject age 20 80 , inclusive ( time inform consent ) Subjects survival expectancy least 3 month Eastern Cooperative Oncology Group ( ECOG ) Performance Status score ( PS score ) 0 2 Subjects inpatient admit trial site duration trial Subjects , together partner , able practice one specify contraceptive method 4 week final trial drug administration Subjects capable give informed consent participate trial free prior start trial . Subjects follow complication symptom : Deep vein thrombosis Intestinal obstruction intestinal edema symptom similar intestinal obstruction Hepatic cirrhosis Anuria Urination impair due urinary tract stricture , urinary calculus , tumor urinary tract , cause Continuing symptom diarrhea vomit Infection require systemic treatment Subjects follow medical history : History cerebrovascular disorder coronary disease within 4 week prior start preobservation period History hypersensitivity idiosyncratic reaction benzazepine derivative mozavaptan hydrochloride benazepril hydrochloride History gastrectomy enterectomy extent affect absorption oral medication Subjects follow abnormal laboratory value : Platelet count &lt; 75,000/mm3 , hemoglobin &lt; 8.0 g/dL , neutrophil count &lt; 1,000/mm3 , total bilirubin &gt; 4.0 g/dL , serum creatinine &gt; 3.0 mg/dL , serum sodium &gt; 147 mEq/L , serum potassium &gt; 5.5 mEq/L Subjects use albumin product ( agent treat hypoalbuminemia ) blood product contain albumin within 1 week prior start preobservation period , start preobservation period Subjects receive investigational drug within 4 week prior start preobservation period Subjects previously receive OPC41061 Subjects receive surgical treatment radiation therapy cancer within 4 week prior start preobservation period Subjects investigator subinvestigator judge would difficult evaluate efficacy safety OPC41061 due effect ongoing chemotherapy therapy cancer ( eg , improvement carcinomatous ascites development edema due adverse event relate therapeutic intervention OPC41061 ) Subjects unable sense thirst difficulty fluid food intake Subjects unable take oral medication Female subject pregnant , possibly pregnant , nursing , plan become pregnant trial period Subjects otherwise judge investigator subinvestigator inappropriate inclusion trial</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>